High endothelin-converting enzyme-1 expression independently predicts poor survival of patients with esophageal squamous cell carcinoma

Ching Fang Wu, Ching Tai Lee, Yao Hung Kuo, Tzu Haw Chen, Chi Yang Chang, I. Wei Chang, Wen Lun Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with esophageal squamous cell carcinoma have poor survival and high recurrence rate, thus an effective prognostic biomarker is needed. Endothelin-converting enzyme-1 is responsible for biosynthesis of endothelin-1, which promotes growth and invasion of human cancers. The role of endothelin-converting enzyme-1 in esophageal squamous cell carcinoma is still unknown. Therefore, this study investigated the significance of endothelin-converting enzyme-1 expression in esophageal squamous cell carcinoma clinically. We enrolled patients with esophageal squamous cell carcinoma who provided pretreated tumor tissues. Tumor endothelin-converting enzyme-1 expression was evaluated by immunohistochemistry and was defined as either low or high expression. Then we evaluated whether tumor endothelin-converting enzyme-1 expression had any association with clinicopathological findings or predicted survival of patients with esophageal squamous cell carcinoma. Overall, 54 of 99 patients with esophageal squamous cell carcinoma had high tumor endothelin-converting enzyme-1 expression, which was significantly associated with lymph node metastasis (p = 0.04). In addition, tumor endothelin-converting enzyme-1 expression independently predicted survival of patients with esophageal squamous cell carcinoma, and the 5-year survival was poorer in patients with high tumor endothelin-converting enzyme-1 expression (p = 0.016). Among patients with locally advanced and potentially resectable esophageal squamous cell carcinoma (stage II and III), 5-year survival was poorer with high tumor endothelin-converting enzyme-1 expression (p = 0.003). High tumor endothelin-converting enzyme-1 expression also significantly predicted poorer survival of patients in this population. In patients with esophageal squamous cell carcinoma, high tumor endothelin-converting enzyme-1 expression might indicate high tumor invasive property. Therefore, tumor endothelin-converting enzyme-1 expression could be a good biomarker to identify patients with worse survival and higher risks of recurrence, who might benefit from the treatment by endothelin-converting enzyme-1 inhibitor.

Original languageEnglish
JournalTumor Biology
Volume39
Issue number9
DOIs
Publication statusPublished - Sep 1 2017
Externally publishedYes

Fingerprint

Survival
Neoplasms
Endothelin-Converting Enzymes
Esophageal Squamous Cell Carcinoma
Biomarkers
Recurrence
Enzyme Inhibitors
Endothelin-1
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis
Growth
Population

Keywords

  • Endothelin-converting enzyme-1
  • esophageal squamous cell carcinoma
  • survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

High endothelin-converting enzyme-1 expression independently predicts poor survival of patients with esophageal squamous cell carcinoma. / Wu, Ching Fang; Lee, Ching Tai; Kuo, Yao Hung; Chen, Tzu Haw; Chang, Chi Yang; Chang, I. Wei; Wang, Wen Lun.

In: Tumor Biology, Vol. 39, No. 9, 01.09.2017.

Research output: Contribution to journalArticle

Wu, Ching Fang ; Lee, Ching Tai ; Kuo, Yao Hung ; Chen, Tzu Haw ; Chang, Chi Yang ; Chang, I. Wei ; Wang, Wen Lun. / High endothelin-converting enzyme-1 expression independently predicts poor survival of patients with esophageal squamous cell carcinoma. In: Tumor Biology. 2017 ; Vol. 39, No. 9.
@article{c60f1bd221da449cbdaa5a98c154700e,
title = "High endothelin-converting enzyme-1 expression independently predicts poor survival of patients with esophageal squamous cell carcinoma",
abstract = "Patients with esophageal squamous cell carcinoma have poor survival and high recurrence rate, thus an effective prognostic biomarker is needed. Endothelin-converting enzyme-1 is responsible for biosynthesis of endothelin-1, which promotes growth and invasion of human cancers. The role of endothelin-converting enzyme-1 in esophageal squamous cell carcinoma is still unknown. Therefore, this study investigated the significance of endothelin-converting enzyme-1 expression in esophageal squamous cell carcinoma clinically. We enrolled patients with esophageal squamous cell carcinoma who provided pretreated tumor tissues. Tumor endothelin-converting enzyme-1 expression was evaluated by immunohistochemistry and was defined as either low or high expression. Then we evaluated whether tumor endothelin-converting enzyme-1 expression had any association with clinicopathological findings or predicted survival of patients with esophageal squamous cell carcinoma. Overall, 54 of 99 patients with esophageal squamous cell carcinoma had high tumor endothelin-converting enzyme-1 expression, which was significantly associated with lymph node metastasis (p = 0.04). In addition, tumor endothelin-converting enzyme-1 expression independently predicted survival of patients with esophageal squamous cell carcinoma, and the 5-year survival was poorer in patients with high tumor endothelin-converting enzyme-1 expression (p = 0.016). Among patients with locally advanced and potentially resectable esophageal squamous cell carcinoma (stage II and III), 5-year survival was poorer with high tumor endothelin-converting enzyme-1 expression (p = 0.003). High tumor endothelin-converting enzyme-1 expression also significantly predicted poorer survival of patients in this population. In patients with esophageal squamous cell carcinoma, high tumor endothelin-converting enzyme-1 expression might indicate high tumor invasive property. Therefore, tumor endothelin-converting enzyme-1 expression could be a good biomarker to identify patients with worse survival and higher risks of recurrence, who might benefit from the treatment by endothelin-converting enzyme-1 inhibitor.",
keywords = "Endothelin-converting enzyme-1, esophageal squamous cell carcinoma, survival",
author = "Wu, {Ching Fang} and Lee, {Ching Tai} and Kuo, {Yao Hung} and Chen, {Tzu Haw} and Chang, {Chi Yang} and Chang, {I. Wei} and Wang, {Wen Lun}",
year = "2017",
month = "9",
day = "1",
doi = "10.1177/1010428317725922",
language = "English",
volume = "39",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "9",

}

TY - JOUR

T1 - High endothelin-converting enzyme-1 expression independently predicts poor survival of patients with esophageal squamous cell carcinoma

AU - Wu, Ching Fang

AU - Lee, Ching Tai

AU - Kuo, Yao Hung

AU - Chen, Tzu Haw

AU - Chang, Chi Yang

AU - Chang, I. Wei

AU - Wang, Wen Lun

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Patients with esophageal squamous cell carcinoma have poor survival and high recurrence rate, thus an effective prognostic biomarker is needed. Endothelin-converting enzyme-1 is responsible for biosynthesis of endothelin-1, which promotes growth and invasion of human cancers. The role of endothelin-converting enzyme-1 in esophageal squamous cell carcinoma is still unknown. Therefore, this study investigated the significance of endothelin-converting enzyme-1 expression in esophageal squamous cell carcinoma clinically. We enrolled patients with esophageal squamous cell carcinoma who provided pretreated tumor tissues. Tumor endothelin-converting enzyme-1 expression was evaluated by immunohistochemistry and was defined as either low or high expression. Then we evaluated whether tumor endothelin-converting enzyme-1 expression had any association with clinicopathological findings or predicted survival of patients with esophageal squamous cell carcinoma. Overall, 54 of 99 patients with esophageal squamous cell carcinoma had high tumor endothelin-converting enzyme-1 expression, which was significantly associated with lymph node metastasis (p = 0.04). In addition, tumor endothelin-converting enzyme-1 expression independently predicted survival of patients with esophageal squamous cell carcinoma, and the 5-year survival was poorer in patients with high tumor endothelin-converting enzyme-1 expression (p = 0.016). Among patients with locally advanced and potentially resectable esophageal squamous cell carcinoma (stage II and III), 5-year survival was poorer with high tumor endothelin-converting enzyme-1 expression (p = 0.003). High tumor endothelin-converting enzyme-1 expression also significantly predicted poorer survival of patients in this population. In patients with esophageal squamous cell carcinoma, high tumor endothelin-converting enzyme-1 expression might indicate high tumor invasive property. Therefore, tumor endothelin-converting enzyme-1 expression could be a good biomarker to identify patients with worse survival and higher risks of recurrence, who might benefit from the treatment by endothelin-converting enzyme-1 inhibitor.

AB - Patients with esophageal squamous cell carcinoma have poor survival and high recurrence rate, thus an effective prognostic biomarker is needed. Endothelin-converting enzyme-1 is responsible for biosynthesis of endothelin-1, which promotes growth and invasion of human cancers. The role of endothelin-converting enzyme-1 in esophageal squamous cell carcinoma is still unknown. Therefore, this study investigated the significance of endothelin-converting enzyme-1 expression in esophageal squamous cell carcinoma clinically. We enrolled patients with esophageal squamous cell carcinoma who provided pretreated tumor tissues. Tumor endothelin-converting enzyme-1 expression was evaluated by immunohistochemistry and was defined as either low or high expression. Then we evaluated whether tumor endothelin-converting enzyme-1 expression had any association with clinicopathological findings or predicted survival of patients with esophageal squamous cell carcinoma. Overall, 54 of 99 patients with esophageal squamous cell carcinoma had high tumor endothelin-converting enzyme-1 expression, which was significantly associated with lymph node metastasis (p = 0.04). In addition, tumor endothelin-converting enzyme-1 expression independently predicted survival of patients with esophageal squamous cell carcinoma, and the 5-year survival was poorer in patients with high tumor endothelin-converting enzyme-1 expression (p = 0.016). Among patients with locally advanced and potentially resectable esophageal squamous cell carcinoma (stage II and III), 5-year survival was poorer with high tumor endothelin-converting enzyme-1 expression (p = 0.003). High tumor endothelin-converting enzyme-1 expression also significantly predicted poorer survival of patients in this population. In patients with esophageal squamous cell carcinoma, high tumor endothelin-converting enzyme-1 expression might indicate high tumor invasive property. Therefore, tumor endothelin-converting enzyme-1 expression could be a good biomarker to identify patients with worse survival and higher risks of recurrence, who might benefit from the treatment by endothelin-converting enzyme-1 inhibitor.

KW - Endothelin-converting enzyme-1

KW - esophageal squamous cell carcinoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85031427681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031427681&partnerID=8YFLogxK

U2 - 10.1177/1010428317725922

DO - 10.1177/1010428317725922

M3 - Article

VL - 39

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 9

ER -